ArticleFuture oncology (London, England)2025

Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.

Martin Reck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.